167 related articles for article (PubMed ID: 35998394)
1. Evaluation of a rapid semiquantitative lateral flow assay for the prediction of serum neutralizing activity against SARS-CoV-2 variants.
Hirabidian M; Bocket L; Demaret J; Vuotto F; Rabat A; Faure K; Labalette M; Hober D; Lefevre G; Alidjinou EK
J Clin Virol; 2022 Oct; 155():105268. PubMed ID: 35998394
[TBL] [Abstract][Full Text] [Related]
2. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum.
Liang D; Zhang G; Huang M; Wang L; Hong W; Li A; Liang Y; Wang T; Lu J; Ou M; Ren Z; Lu H; Zheng R; Cai X; Pan X; Xia J; Ke C
Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558864
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay.
Liu H; Varvel S; Chen G; McConnell J; Caffrey R; Galdzicka M; Shabahang S
Front Immunol; 2022; 13():1039163. PubMed ID: 36505453
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.
Franchini M; Focosi D; Mengoli C; Percivalle E; Sammartino JC; Ferrari A; Zani M; Glingani C; Baldanti F
Transfusion; 2022 Jun; 62(6):1171-1176. PubMed ID: 35426131
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
Front Immunol; 2022; 13():981693. PubMed ID: 36225911
[TBL] [Abstract][Full Text] [Related]
6. Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort.
Zhu L; Mao N; Yi C; Simayi A; Feng J; Feng Y; He M; Ding S; Wang Y; Wang Y; Wei M; Hong J; Li C; Tian H; Zhou L; Peng J; Zhang S; Song C; Jin H; Zhu F; Xu W; Zhao J; Bao C
Emerg Microbes Infect; 2023 Dec; 12(1):2146535. PubMed ID: 36373485
[TBL] [Abstract][Full Text] [Related]
7. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
[TBL] [Abstract][Full Text] [Related]
8. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
[TBL] [Abstract][Full Text] [Related]
11. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
12. Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.
Takheaw N; Liwsrisakun C; Chaiwong W; Laopajon W; Pata S; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
Diagnostics (Basel); 2022 May; 12(6):. PubMed ID: 35741126
[TBL] [Abstract][Full Text] [Related]
13. Multiplexed evaluation of immunity against SARS-CoV-2 variants using surface enhanced fluorescence from a nanostructured plasmonic chip.
Hu R; Yang Y; Liu Y; Liao T; Liu Y; Tang J; Wang G; Wang G; Liang Y; Yuan J; Zhang B
J Nanobiotechnology; 2022 Dec; 20(1):533. PubMed ID: 36522786
[TBL] [Abstract][Full Text] [Related]
14. Detection of SARS-CoV-2 Neutralizing Antibodies in Vaccinated Pregnant Women and Neonates by Using a Lateral Flow Immunoassay Coupled with a Spectrum-Based Reader.
Chen WC; Lin YP; Cheng CM; Shen CF; Li CW; Wang YK; Shih TY; Hong C; Chang TC; Shen CJ
Biosensors (Basel); 2022 Oct; 12(10):. PubMed ID: 36291029
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Value of a SARS-CoV-2 Rapid Test Kit for Detection of Neutralizing Antibodies as a Point-of-Care Surveillance Test.
Chan MMH; Leung KY; Zhang RRQ; Liu D; Fan Y; Khong MKW; Tam AR; Chen H; Yuen KY; Hung IFN; Chan KH
Microbiol Spectr; 2022 Apr; 10(2):e0099321. PubMed ID: 35254121
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies.
Zedan HT; Yassine HM; Al-Sadeq DW; Liu N; Qotba H; Nicolai E; Pieri M; Bernardini S; Abu-Raddad LJ; Nasrallah GK
Sci Rep; 2022 Nov; 12(1):19020. PubMed ID: 36347859
[TBL] [Abstract][Full Text] [Related]
17. Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies.
Pieri M; Nicolai E; Nuccetelli M; Sarubbi S; Tomassetti F; Pelagalli M; Minieri M; Terrinoni A; Bernardini S
Arch Virol; 2022 May; 167(5):1285-1291. PubMed ID: 35377034
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals.
Moy JN; Anderson M; Shen X; Fu J; Stec M; Gosha A; Naquiallah D; Kinslow J; Montefiori DC; Cloherty G; Landay A
J Infect Dis; 2022 Oct; 226(8):1407-1411. PubMed ID: 35759252
[TBL] [Abstract][Full Text] [Related]
19. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China.
Yan LN; Zhao ZX; Wang ZD; Xiao X; Liu PP; Zhang WK; Gu XL; Li B; Yu LP; Yu XJ
Expert Rev Vaccines; 2022 Oct; 21(10):1465-1473. PubMed ID: 35861138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]